ARTICLE | Clinical News
Neotrofin leteprinim (AIT-082): Completed Phase II/III study enrollment
September 10, 2001 7:00 AM UTC
NeoTherapeutics Inc. (NEOT), Irvine, Calif. Product: Neotrofin leteprinim (AIT-082) Business: Neurological Therapeutic category: Growth factor, Nerve regeneration Target: Neurotrophic factors Descript...